The Long Learning Curve For Artificially Intelligent Drug Manufacturing Begins Now

Drugmakers quickly adopt low-impact AI/ML models in quest to eventually automate manufacturing processes. Already, they are learning a lot about how these models can support their operations. One finding: innovative change management approaches may be required to unlock their full potential.

Big machine learning curve
the human learning curve comes first • Source: Shutterstock

The pharmaceutical sector has quickly begun using artificial intelligence and machine learning models (AI/ML) in manufacturing and quality assurance, participants in recent workshop discussions indicated – but is unlikely to give the technology control over manufacturing processes or product release anytime soon.

Meanwhile, pharmaceutical manufacturers are working to optimize the AI/ML models they are using, for example by relying on recent regulatory...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Manufacturing Focus

Why CAR T Therapies Are Hard To Scale, And How Challenges Can Be Solved

 

Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of blood cancer, but scalability remains a major challenge. Experts explain how technologies such as chip-based miniaturized models and automation could be part of the solution.  

How Cellino’s Cassette Technology Will Impact Regenerative Medicine

 
• By 

Co-founder and CEO of Cellino Biotech, Nabiha Saklayen, discusses the company’s innovative platform which uses automated technologies to overcome challenges in the development of regenerative medicine.

Agnė Vaitkevičienė: The Versatile CEO Driving Memel Biotech

 

Rising star Agnė Vaitkevičienė is juggling roles as the CEO of an emerging Lithuanian biotech, with work for a partner company, the national biotech trade association and much more.   

China VBP, Localization And Other Strategies - How Far And Which Way?

 
• By 

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues. 

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By 

XXXXtesting